Role of Endogenous GLP-1 and its Agonists in Osteopenia and Osteoporosis: But We Little Know Until Tried

Title:Role of Endogenous GLP-1 and its Agonists in Osteopenia and Osteoporosis: But We Little Know Until Tried

Volume: 10 Issue: 1

Author(s): Athanasia Papazafiropoulou, Nikolaos Papanas, Stavros Pappas and Efstratios Maltezos

Affiliation:

Keywords: Bone metabolism, fractures, GLP-1, incretins, type 2 diabetes mellitus.

Abstract: The present brief review looks at the evidence on the role of GLP-1 and its agonists in osteopenia and osteoporosis in type 2 diabetes (T2DM). There is accumulating data to suggest a favourable effect of GLP-1 on bone metabolism. However, most data is from experimental studies, while clinical confirmation is still inadequate. Moreover, little is known on the precise mechanisms underlying these effects. Therefore, we need randomised clinical trials in T2DM patients to learn more on the action of GLP-1 on bone metabolism and its potential clinical implications.

Cite this article as:

Papazafiropoulou Athanasia, Papanas Nikolaos, Pappas Stavros and Maltezos Efstratios, Role of Endogenous GLP-1 and its Agonists in Osteopenia and Osteoporosis: But We Little Know Until Tried, Current Diabetes Reviews 2014; 10 (1) . https://dx.doi.org/10.2174/1573399810666140217114848